Breast Cancer Clinical Trial

PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions

Summary

This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and/or ductal carcinoma in situ (DCIS))

View Full Description

Full Description

The goal of this research is to better understand the experience of women who have been diagnosed with certain breast conditions to enable women (and their doctors) to make informed decisions about their care.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients treated at DUMC, DFCI, MDACC, MGH, NWH, or DFCI @ SSH with a diagnosis of DCIS, LCIS, ADH, or ALH who are also:

Age 18 or more at index diagnosis
Diagnosed with DCIS, LCIS, ADH, or ALH between January 1, 2012 and June 30, 2017
Able to read either English or Spanish and able to provide written (via paper), or on-line informed consent
Treated and followed at one of the study sites (including affiliated network sites) and for whom treatment and surveillance data are available, for at least 1 year of follow up after date of diagnosis
Participants with bilateral synchronous or metachronous disease (DCIS, LCIS, ADH, ALH) are eligible

Exclusion Criteria:

Ever had a diagnosis of invasive or microinvasive breast cancer
DCIS prior to index lesion or history of progressive/recurrent DCIS after treatment
Other cancers (excluding non-melanoma skin cancer) diagnosed within 5 years prior to index lesion, including concurrent invasive cancer diagnosis and up to the present time of participant's approach to invitation into the study
Patients identified by treating physician as being unsuitable for contact

Study is for people with:

Breast Cancer

Estimated Enrollment:

912

Study ID:

NCT03070236

Recruitment Status:

Active, not recruiting

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Newton-Wellesley Hospital
Newton Massachusetts, 02462, United States
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
Weymouth Massachusetts, 02198, United States
Duke University Medical Center
Durham North Carolina, 27710, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

912

Study ID:

NCT03070236

Recruitment Status:

Active, not recruiting

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.